

# DEFEATING MENINGITIS BY 2030 A GLOBAL ROAD MAP







Defeating meningitis by 2030: a global road map

ISBN 978-92-4-002640-7 (electronic version) ISBN 978-92-4-002641-4 (print version)

#### © World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<a href="http://www.wipo.int/amc/en/mediation/rules/">http://www.wipo.int/amc/en/mediation/rules/</a>).

Suggested citation. Defeating meningitis by 2030: a global road map. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see <a href="http://apps.who.int/bookorders">http://apps.who.int/bookorders</a>. To submit requests for commercial use and queries on rights and licensing, see <a href="http://www.who.int/about/licensing">http://www.who.int/about/licensing</a>.

**Third-party materials**. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## **Contents**

Acknowledgements	IV
Abbreviations and acronyms	VI
Executive summary	1
Meningitis – a call for action	2
Scope	4
Vision	4
Visionary goals by 2030	4
Pillars, strategic goals, key activities and milestones	5
Wider benefits and complementarity	6
Implementation	6
Pillar 1: Prevention and epidemic control	7
Pillar 2: Diagnosis and treatment	12
Pillar 3: Disease surveillance	14
Pillar 4: Support and care for people affected by meningitis	16
Pillar 5: Advocacy and engagement	18
Connection to other global initiatives	21
Key references	22

#### **Acknowledgements**

This document is the result of a significant technical contribution and the collaborative efforts of the WHO Technical Taskforce on Defeating Meningitis by 2030, coordinated by the WHO core secretariat of the Technical Taskforce: Marie-Pierre Preziosi, James Stuart (consultant), Antoine Durupt, Olivier Ronveaux, Katya Fernandez, Tarun Dua and Nicoline Schiess.

The Technical Taskforce on Defeating Meningitis by 2030 includes representatives from partner organizations and international experts, listed in alphabetical order of representing organization and the last names of individuals:

Centers for Disease Control and Prevention, Atlanta,
United States of America: LeAnne Fox, Lucy McNamara,
Ryan Novak; London School of Hygiene and Tropical
Medicine, London, United Kingdom of Great Britain and
Northern Ireland: Brian Greenwood, Beate Kampmann,
Joy Lawn; Médecins Sans Frontières and Epicentre,
Brussels, Belgium; Geneva, Switzerland; Paris, France: Iza
Ciglenecki, Matthew Coldiron,
Myriam Henkens; Meningitis Research Foundation,
Bristol, United Kingdom: Linda Glennie, Vincent Smith;
PATH, Seattle, United States of America: Mark Alderson:

Ciglenecki, Matthew Coldiron, Myriam Henkens; Meningitis Research Foundation, Bristol, United Kingdom: Linda Glennie, Vincent Smith; PATH, Seattle, United States of America: Mark Alderson; **UNICEF Program Division, New York City, United States** of America: Suleman Malik, Imran Mirza; International experts: Dominique Caugant, National Institute of Public Health, Oslo, Norway; Nora Groce, University College London, London, United Kingdom; Robert Heyderman, University College London, London, United Kingdom; Keith Klugman, Bill & Melinda Gates Foundation, Seattle, United States of America; Gail Rodgers, Bill & Melinda Gates Foundation, Seattle, United States of America; Caroline Trotter, University of Cambridge, Cambridge, United Kingdom; WHO/headquarters and Regional Offices: Regional Office for Africa: André Bita, Mamoudou Harouna Djingarey, Anderson Latt, Richard Mihigo, Helena O'Malley; Regional Office for the Americas: Lucia de Oliveira; Regional Office for the Eastern Mediterranean: Nadia Teleb Badr; Regional Office for Europe: Siddhartha Datta, Liudmila Mosina; Regional Office for South-East Asia: Emmanuel Njambe Tondo Opute; Regional Office for Western Pacific: James Heffelfinger; Headquarters: Adam Cohen, Tarun Dua, Antoine Durupt, Katya Fernandez, William Perea, Marie-Pierre Preziosi, Olivier Ronveaux, Nicoline Schiess, Fatima Serhan, James Stuart (consultant), Carol Tevi Benissan, Eduardo Vargas Garcia.

This road map was developed through a series of consultation meetings involving representatives from governments, global health organizations, public health bodies, academia, the private sector and civil society and through wide public consultation including patient groups around the world. WHO also wishes to thank the following individuals for their vital contribution to the development of this road map through participation at consultation meetings at Wilton Park, United Kingdom in February 2019 and/or at the Wellcome Trust, United Kingdom in September 2019 or through responses to the web-based consultation in July 2019:

African Disability Alliance, Malawi: Action Amos; Angela Hwang Consulting, United States of America: Angela Hwang; Asociación Española contra la Meningitis, Spain: Elena Moya; Bill & Melinda Gates Foundation, United States of America: Nicole Benson, Kate Fay; bioMérieux, France: Maria-Fernanda Ruiz; Care and Development Centre, Nigeria: Omorodion Rhoda Omoile; Centers for Disease Control and Prevention, Atlanta, United States of America: Allen Craig, Fernanda Lessa, Kim Fox, Stephanie Schrag, Heidi Soeters, Xin Wang; Child Health Research Foundation, Bangladesh: Senjuti Saha; Chinese Center for Disease Control and Prevention, China: Zhujun Shao; Confederation of Meningitis Organizations, United Kingdom: Linda Gibbs, Sam Nye; Developing Countries Vaccine Manufacturers Network, Switzerland: Sonia Pagliusi; Dhaka Shishu Hospital, Bangladesh: Samir Saha; **Emory University, United States of America:** David Stephens; Every Breath Counts Coalition, Nigeria: Leith Greenslade; Fighting Infectious Diseases in Emerging Countries, Argentina: Ricardo Rüttimann; Foundation for Innovative New Diagnostics, **Switzerland:** Ranga Sampath; **Finlay, Cuba:** Dagmar Garcia Rivera; Fiocruz, Brazil: Ivano De Filippis; Ghana Health Service, Ghana: Abraham Hodgson; Gavi, the Vaccine Alliance, Switzerland: Aurelia Nguyen, Zeenat Patel, Cassandra Quintanilla; GlaxoSmithKline, Belgium: Bindi Patel; Global Healthcare Consulting, United States of America: Sonali Kochhar; Group B Strep International, United States of America: Marti Perhach; Group B Strep Support, United Kingdom: Jane Plumb; Hospital del Niño Dr. José Renán Esquivel, Panama: Xavier Saez Llorens: International Federation of Pharmaceutical Manufacturers & Associations, Switzerland: Laetitia Bigger; Independent expert, United States of America: Lesley-Anne Long; Institut Pasteur, France: Muhamed-Kheir Taha; Institut Pasteur, Viet Nam: Thuong Nguyen; **International Vaccine Access Center, Johns Hopkins** Bloomberg School of Public Health, United States of America: Lois Privor-Dumm, Maria Deloria Knoll;

London School of Hygiene and Tropical Medicine, United Kingdom: Hannah Kuper; Malaria Consortium, United Kingdom: Prudence Hamade; Meningitis Centre Australia, Australia: Lisa D'Cruz; Meningitis Now, United Kingdom: Tom Nutt; Meningitis Research Foundation, United Kingdom: Natacha Blake, Rob Dawson, Chloe Day, Elizabeth Rodgers, Claire Wright; MiCo Biomed, Republic of Korea: Sung-Woo Kim; Ministry of Health, Tonga: Toa Fakakovikaetau; Ministry of Health, Togo: Hamadi Assane; Ministry of Health, Spain: Aurora Limia Sanchez, Laura Sánchez-Cambronero Cejudo; Ministry of Health, Saudi Arabia: Ziad Memish; Ministry of Health, Fiji: Aalisha Sahukhan; National Institute for Communicable Diseases, South Africa: Anne von Gottberg; Nigeria Centre for Disease Control, Nigeria: Priscilla Ibekwe; PATH, United States of America: Niranjan Bhat, Anthony Marfin, Roger Peck; Pfizer, France and United States of America: Jamie Findlow, Brad Gessner, Marie-Christine Truchet; Public Health England, United Kingdom: Ray Borrow; QuantuMDX, United Kingdom: David Dolinger; Sanofi Pasteur, France: Priscille De la Tour, Sandra Guedes, Philipp Oster; Save the Children UK, United Kingdom: Tahlil Ahmed; Serum Institute of India Pvt. Ltd, India: Suresh Jadhav, Francois Marc LaForce; St George's University of London, United Kingdom: Kirsty Le Doare; The MenB Project/The Emily Stillman Foundation, United States of America: Alicia Stillman; The Royal Children's Hospital, Australia: Claire von Mollendorf; Una Vida por Dakota, Peru: Gianina Orellana Tarazona; Universidad de Chile, Chile: Rodolfo Villena; University College London, United Kingdom: Maria Kett; University College London, The Gambia: Brenda Kwambana-Adams; University of Melbourne, Australia: Fiona Russell; University of Oxford, United Kingdom: Martin Maiden; University of the Philippines/ Philippine General Hospital, Philippines: Marimel Reyes-Pagcatipunan; University of Liverpool, United Kingdom: Michael Griffiths; Wake Forest University School of Medicine, United States of America: Jon Abramson; Walvax, China: Neal Xiao, Aaron Yang; Wellcome Trust, United Kingdom: Josie Golding, Peter Hart, Charlie Weller; Wilton Park, United Kingdom: Robin Hart; Zhifei, China: Lin Du, Jia Tian; and WHO/headquarters and Regional Offices: Regional Office for Africa: Clément Lingani; Regional Office for the Americas: Maria Tereza da Costa Oliveira, Antonny Duttine, Gloria Rey, Andrea Vicari; Headquarters: Virginia Benassi, Shalini Desai, Hayatee Hasan, Philipp Lambach, Claudia Nannei, Ikechukwu Udo Ogbuanu, Irena Prat, Johan Vekemans, Patrick Zuber.

WHO advisory groups, the Strategic and Technical Advisory Group for Infectious Hazards (STAG-IH) and the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed the road map, in June 2019 and October 2019 respectively.

Information sessions and road map consultations with Member States took place between October 2019 and May 2020. The Seventy-third World Health Assembly approved the road map in November 2020 (resolution WHA73.9). The definitive version of the global road map on defeating meningitis by 2030 can be found in the official records of the Seventy-third World Health Assembly (document WHA73/2020/REC/1, Annex 4).

This document has been produced with the financial assistance of the Bill & Melinda Gates Foundation, the United Kingdom's Foreign, Commonwealth & Development Office (formerly the Department for International Development) and the Wellcome Trust.

### **Abbreviations and acronyms**

Gavi Gavi, the Vaccine Alliance
GBS group B streptococcus
Hi Haemophilus influenzae

Hia Haemophilus influenzae type a
Hib Haemophilus influenzae type b
HIV human immunodeficiency virus

Nm Neisseria meningitidis

PAHO Pan-American Health Organization
SEARO WHO Regional Office for South-East Asia

Spn Streptococcus pneumoniae
UNICEF United Nations Children's Fund
WHO World Health Organization

WPRO WHO Regional Office for the Western Pacific

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5\_23769

